Medtronic's Q2 Results Fuel Growth Hopes, But Analysts Remain Skeptical

Medtronic reported Q2 revenue of $8.961 billion, beating consensus estimates, and raised its full-year organic revenue growth guidance to 5.5%. The company's strong performance was driven by the Cardiovascular and Diabetes businesses, but operating margins contracted and missed consensus estimates. Analysts say the growth story is improving, but the stock already reflects optimism around Medtronic's pipeline.